Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Rothmann

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
The Oncologist|January 8, 2011
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemiaSandra J Casak, Steven J Lemery, Yuan Li Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2010
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumabSteven J Lemery, Jenny Zhang, Mark D Rothmann, et al.
Therapeutic Innovation & Regulatory Science|September 3, 2022
Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric ExtrapolationThomas R Fleming, Christine E Garnett, Laurie S Conklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2012
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosisAlbert Deisseroth, Edvardas Kaminskas, Joseph Grillo, et al.
The Oncologist|December 7, 2013
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemiaFiroozeh Alvandi, Virginia E Kwitkowski, Chia-Wen Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2013
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myelomaThomas M Herndon, Albert Deisseroth, Edvardas Kaminskas, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Oncologist|January 8, 2011
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemiaSandra J Casak, Steven J Lemery, Yuan Li Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2010
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumabSteven J Lemery, Jenny Zhang, Mark D Rothmann, et al.
Therapeutic Innovation & Regulatory Science|September 3, 2022
Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric ExtrapolationThomas R Fleming, Christine E Garnett, Laurie S Conklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2012
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosisAlbert Deisseroth, Edvardas Kaminskas, Joseph Grillo, et al.
The Oncologist|December 7, 2013
U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemiaFiroozeh Alvandi, Virginia E Kwitkowski, Chia-Wen Ko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2013
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myelomaThomas M Herndon, Albert Deisseroth, Edvardas Kaminskas, et al.
Pageof 2